NASDAQ:STTK
Shattuck Labs, Inc. Stock Company Profile
$11.18
+0.400 (+3.71%)
At Close: May 06, 2024
Information
500 West 5th Street, Suite 1200
Austin TX 78703
512 900 4690
www.shattucklabs.com
Industry: Biotechnology
Sector: Healthcare
Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.